CD137 and CD200 Checkpoint Expression in Lung Cancer Lymph Node Aspirates

71 lung cancer patient lymph node aspirates analyzed via flow cytometry for immune checkpoint expression. The dataset includes expression levels of CD137, CD137L, CD200, CD200R, PD-1, PD-L1, and PD-L2 on tumor cells and lymphocytes. It was authored by Iwona Kwiecień and last updated on 2026-05-26.

Use Cases

• Correlating non-classical checkpoint expression with PD-1/PD-L1 pathways based on flow cytometry data.
• Comparing immune checkpoint profiles between NSCLC and other histologies based on marker expression levels.
• Investigating associations between tumor cell and lymphocyte marker expression within the lymph node microenvironment.

Strengths

• Data from 71 patient samples provides a specific cohort size.
• Includes analysis of seven specific immune checkpoint markers (CD137, CD137L, CD200, CD200R, PD-1, PD-L1, PD-L2).
• Expression data is separated for tumor cells and lymphocytes, offering cell-type specificity.

Limitations

• Row count and column-level documentation are unknown, limiting suitability assessment.
• The dataset is very small at 16.7 KB, indicating limited scope.
• Data is contained in a DOCX file, which may require extraction to access structured data.

Provenance

Source

figshare

Collection Method

Lymph node aspirates obtained via transbronchial needle aspiration biopsy (EBUS/TBNA) and analyzed using cytology, hematological screening, and flow cytometry.

Freshness

Last updated 2026-05-26 06:03:47; freshness should be verified.